A group of researchers at Washington State University has received four expressions of concern for papers whose findings underpin a publicly traded company founded by two of the most senior authors on the articles.
The studies, all of which appeared in the Journal of Pharmacology and Experimental Therapeutics, came from the labs of Joseph Harding, a medical chemist at Washington State, and his colleague Jay Wright. Published between 2011 and 2014, the four articles report on a molecule called angiotensin IV, work which Harding and Wright leveraged to spin-off Athira, a Seattle-based biotech firm developing treatments for conditions including Alzheimer’s and Parkinson’s disease.
The CEO of Athira, formerly known as M3 Biotechnology, is Leen Kawas, once a PhD student at Washington State whose 2011 doctoral dissertation provided figures for this fraught 2011 article in JPET, which earned a correction in 2014. Earlier this year, as STAT reported, Kawas was forced to take a leave of absence from the company over concerns that she altered images in several papers. And there has been other scrutiny of the company.
Continue reading Four papers by Athira CEO earn expressions of concern